Hepatitis B virus traceback and lookback: Factors to consider

Transfusion

Volumn 49, Issue 1, 2009, Pages 176-184

  Hollinger, F Blaine ^a   Dodd, Roger Y ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; PROPIOLACTONE; YELLOW FEVER VACCINE;

BLOOD COMPONENT; BLOOD DONOR; BLOOD TRANSFUSION; EVIDENCE BASED PRACTICE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INCUBATION TIME; INFECTION RISK; MEDICAL DECISION MAKING; POSTTRANSFUSION HEPATITIS; RECIPIENT; REVIEW;

BLOOD DONORS; BLOOD TRANSFUSION; DONOR SELECTION; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; INFECTIOUS DISEASE INCUBATION PERIOD;

EID: 58149122730     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2008.01961.x     Document Type: Review

References (43)

1. Dodd RY, Notari EP, Stramer SL. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion 2002 42 : 975 9.
2. Busch MP, Glynn SA, Stramer SL, Strong DM, Caglioti S, Wright DJ, Pappalardo B, Kleinman SH. A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors. Transfusion 2005 45 : 254 64.
3. Petersen LR, Satten GA, Dodd R, Busch M, Kleinman S, Grindon A, Lenes B. Duration of time from onset of human immunodeficiency virus type 1 infectiousness to development of detectable antibody. Transfusion 1994 34 : 283 9.
4. Culver DH, Alter MJ, Mullan RJ, Margolis HS. Evaluation of the effectiveness of targeted lookback for HCV infection in the United States - interim results. Transfusion 2000 40 : 1176 81.
5. Hollinger FB. Hepatitis B virus infection and transfusion medicine: science and the occult. Transfusion 2008 48 : 1001 26.
6. Stramer SL. Pooled hepatitis B virus DNA testing by nucleic acid amplification: implementation or not. Transfusion 2005 45 : 1242 6.
7. Sawyer WA, Meyer KF, Eaton MD, Bauer JH, Putnam P, Schwentker FF. Jaundice in army personnel in the western region of the United States and its relation to vaccination against yellow fever. Am J Hygiene 1944 39 : 337 429.
8. Havens W Jr. Period of infectivity of patients with homologous serum jaundice and routes of infection in this disease. J Exp Med 1946 83 : 441 7.
9. Neefe J, Gellis S, Stokes JJ. Homologous serum hepatitis and infectious (epidemic) hepatitis: studies in volunteers bearing on immunological and other characteristics of the biological agents. Am J Med 1946 1 : 3 22.
10. Hoofnagle JH, Gerety RJ, Tabor E, Feinstone SM, Barker LF, Purcell RH. Transmission of non-A, non-B hepatitis. Ann Intern Med 1977 87 : 14 20.
11. Barker LF, Murray R. Relationship of virus dose to incubation time of clinical hepatitis and time of appearance of hepatitis-associated antigen. Am J Med Sci 1972 263 : 27 33.
12. Krugman S, Giles JP. Viral hepatitis. New light on an old disease. JAMA 1970 212 : 1019 29.
13. Krugman S, Giles JP. Viral hepatitis, type B (MS-2-strain). Further observations on natural history and prevention. N Engl J Med 1973 288 : 755 60.
14. Grady GF, Lee VA, Prince AM, Gitnick GL, Fawaz KA, Vyas GN, Levitt MD, Senior JR, Galambos JT, Bynum TE, Singleton JW, Clowdus BF, Akdamar K, Aach RD, Winkelman EI, Schiff GM, Hersh T. Hepatitis B immune globulin for accidental exposures among medical personnel: final report of a multicenter controlled trial. J Infect Dis 1978 138 : 625 38.
15. Kleinman SH, Strong DM, Tegtmeier GG, Holland PV, Gorlin JB, Cousins C, Chiacchierini RP, Pietrelli LA. Hepatitis B virus (HBV) DNA screening of blood donations in minipools with the COBAS AmpliScreen HBV test. Transfusion 2005 45 : 1247 57.
16. Kleinman SH, Kuhns MC, Todd DS, Glynn SA, McNamara A, DiMarco A, Busch MP. Frequency of HBV DNA detection in US blood donors testing positive for the presence of anti-HBc: implications for transfusion transmission and donor screening. Transfusion 2003 43 : 696 704.
17. Busch MP. Should HBV DNA NAT replace HBsAg and/or anti-HBc screening of blood donors? Transfus Clin Biol 2004 11 : 26 32.
18. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ. The risk of transfusion-transmitted viral infections. N Engl J Med 1996 334 : 1685 90.
19. Dodd RY, Notari EP, Stramer SL. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion 2002 42 : 975 9.
20. Linauts S, Saldanha J, Strong DM. PRISM hepatitis B surface antigen detection of hepatitis B virus minipool nucleic acid testing yield samples. Transfusion 2008 48 : 1376 82.
21. Stramer SL, Glynn SA, Kleinman SH, Strong DM, Caglioti S, Wright DJ, Dodd RY, Busch MP. Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing. N Engl J Med 2004 351 : 760 8.
22. Seeff LB, Beebe GW, Hoofnagle JH, Norman JE, Buskell-Bales Z, Waggoner JG, Kaplowitz N, Koff RS, Petrini JL Jr., Schiff ER, Shorey J, Stanley MM. A serologic follow-up of the 1942 epidemic of post-vaccination hepatitis in the United States Army. N Engl J Med 1987 316 : 965 70.
23. Alter HJ, Holland PV, Purcell RH. The emerging pattern of post-transfusion hepatitis. Am J Med Sci 1975 270 : 329 34.
24. Simons MJ. Transfusion of hepatitis B immune complex-containing blood in high HBV prevalence populations. Am J Med Sci 1975 270 : 349 54.
25. Hollinger FB, Dreesman GR, Fields H, Melnick J. HBcAg, anti-HBc, and DNA polymerase activity in transfused recipients followed prospectively. Am J Med Sci 1975 270 : 343 8.
26. Pattison CP, Klein CA, Leger RT, Maynard JE, Berquist KR, Hoofnagle JH, Barker LF, Bryan JA, Smith DE. An outbreak of type B hepatitis associated with transfusion of plasma protein fraction. Am J Epidemiol 1976 103 : 399 407.
27. Hollinger FB, Liang TJ. Hepatitis B virus. In : Fields BN, Knipe DM, Howley PM, Chanock RM, Melnick JL, Monath TP, Roizman B, Straus SE, editors. Fields virology. 4th ed. Philadelphia (PA) : Lippincott Williams & Wilkins 2001. p. 2971 3036.
28. Centers for Disease Control and Prevention. Surveillance for acute viral hepatitis - United States, 2006. MMWR 2008 57 : SS 2.
29. Lee WM. Acute liver failure. N Engl J Med 1993 329 : 1862 72.
30. Garfein RS, Bower WA, Loney CM, Hutin YJ, Xia GL, Jawanda J, Groom AV, Nainan OV, Murphy JS, Bell BP. Factors associated with fulminant liver failure during an outbreak among injection drug users with acute hepatitis B. Hepatology 2004 40 : 865 73.
31. Vamvakas EC. Uses and sources of data on long-term survival after blood transfusion. Transfus Med Rev 2003 17 : 194 208.
32. Seeff LB, Hollinger FB, Alter HJ, Wright EC, Cain CM, Buskell ZJ, Ishak KG, Iber FL, Toro D, Samanta A, Koretz RL, Perrillo RP, Goodman ZD, Knodell RG, Gitnick G, Morgan TR, Schiff ER, Lasky S, Stevens C, Vlahcevic RZ, Weinshel E, Tanwandee T, Lin HJ, Barbosa L. Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: a National Heart, Lung, and Blood Institute collaborative study. Hepatology 2001 33 : 455 63.
33. Alter HJ, Seeff LB. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis 2000 20 : 17 35.
34. Yoshiba M, Sekiyama K, Sugata F, Kawamoto Y, Muraoka H, Aoyama M. Posttransfusion fulminant hepatitis B after screening for hepatitis B virus core antibody. Lancet 1992 339 : 253 4.
35. Soldan K, Barbara JA, Dow BC. Transfusion-transmitted hepatitis B virus infection in the UK: a small and moving target. Vox Sang 2002 83 : 305 8.
36. Dow BC, Peterkin MA, Green RH, Cameron SO. Hepatitis B virus transmission by blood donation negative for hepatitis B surface antigen, antibody to HBsAg, antibody to hepatitis B core antigen and HBV DNA. Vox Sang 2001 81 : 140.
37. Inaba S, Ito A, Miyata Y, Ishii H, Kajimoto S, Tanaka M, Maruta A, Saito S, Yugi H, Hino M, Tadokoro K. Individual nucleic amplification technology does not prevent all hepatitis B virus transmission by blood transfusion. Transfusion 2006 46 : 2028 9.
38. Larsen J, Hetland G, Skaug K. Posttransfusion hepatitis B transmitted by blood from a hepatitis B surface antigen-negative hepatitis B virus carrier. Transfusion 1990 30 : 431 2.
39. Satake M, Taira R, Yugi H, Hino S, Kanemitsu K, Ikeda H, Tadokoro K. Infectivity of blood components with low hepatitis B virus DNA levels identified in a lookback program. Transfusion 2007 47 : 1197 205.
40. AuBuchon JP. Paving with good intentions: learning from HCV lookback. Transfusion 2000 40 : 1153 6.
41. Callum JL, Pinkerton PH, Coovadia AS, Thomson AE, Dewsbury F. An evaluation of the process and costs associated with targeted lookbacks for HCV and general notification of transfusion recipients. Transfusion 2000 40 : 1169 75.
42. FDA Memorandum to All Registered Blood and Plasma Establishments. Recommendations for the Quarantine and Disposition of Units from Prior Collections from Donors with Repeatedly Reactive Screening Tests for Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) and Human T-Lymphotropic Virus Type I (HTLV-I). July 19, 1996. Available from: http://www.fda.gov/cber/bldmem/ mem71996.pdf
43. Foster KR, Vecchia P, Repacholi MH. Risk management. Science and the precautionary principle. Science 2000 288 : 979 81.